Kiniksa Pharmaceuticals Financials

Kiniksa Pharmaceuticals

KNSA • NASDAQ •

Values in thousands	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Revenue	$79,858	$83,395	$67,046	$71,473
Gross Profit	48,320	56,636	40,647	49,788
EBITDA	-16,076	317	-10,927	-3,154
EBIT	-16,542	81	-11,530	-3,756
Net Income	-17,704	25,237	-13,855	14,972
Net Change In Cash	79,858	83,395	67,046	71,473
Cost of Revenue				31,949
Free Cash Flow	3,903	4,269	16,970	-3,777
Cash	141,078	107,954	117,828	112,567
Basic Shares	70,633	72,660	70,186	71,634

Values in thousands	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Revenue	$270,259	$220,180	$38,544	$7,704
Gross Profit	179,219	173,214	29,444	-3,805
EBITDA	-23,087	9,773	-154,281	-154,958
EBIT	-25,196	7,371	-156,636	-157,363
Net Income	14,084	183,363	-157,924	-161,381
Net Change In Cash	270,259	220,180	38,544	7,704
Cost of Revenue		245	8,222	67,110
Free Cash Flow	13,171	5,702	-146,713	-136,815
Cash	107,954	122,715	122,470	114,038
Basic Shares	71,922	70,421	68,576	61,842